Global Continuous Glucose Monitoring Systems Market by Components (Sensors, Transmitters & Receivers, and Integrated Insulin Pumps), Demographics (Child Population (<14 years), and Adult Population (>14 years)), and End Users (Diagnostic Centers/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
Continuous Glucose Monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM systems are a type of glucose monitoring devices that function by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in the interstitial fluid or in the blood and results are transmitted via a transmitter to a receiver/monitor that displays the results. CGM systems have emerged as an integral part of diabetes management owing to its several advantages over other glucose monitoring devices. Unlike conventional glucose monitors, these systems enable periodic monitoring of glucose levels, which is crucial to avoid any diabetic complications. In addition, CGMS technology has laid a roadmap to the most awaited, high-tech, closed-loop ‘artificial/bionic pancreas’. Therefore, developing novel and technologically advanced CGMS is the prime focus of several glucose monitoring device manufacturing companies. CGMS offer a wide range of applications across all age-cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs and home healthcare) and geographies. Thus, CGMS market shows lucrative opportunity for both CGMS manufacturers and insulin pump manufacturers.
The global CGMS market is forecast to reach $2.9 billion by 2021 registering a CAGR of 31.4% over the forecast period. The pipeline of high-tech CGMS devices, such as smartphone-connected CGMS, wearable and smartphone-connected CGMS, non-invasive CGMS and ‘smart’ diabetes management solution (also called artificial/bionic pancreas), would result in larger adoption of CGMS among endocrinologists and patients.
The market is categorized based on components, customer segments, end-user demographics and geographic regions. The CGMS components market includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. The segment for sensors occupies a dominant share in the CGMS market primarily due to the recurring sales of CGMS, short scrap life and bulk purchases. CGMS are deployed primarily by the diagnostic centers/clinics. Moreover, increasing usage of CGMS across the hospital ICUs and in-home healthcare settings has been observed. The CGMS devices market by age demographics is categorized as juveniles, Gen X and geriatrics.
Detailed geographical analysis and segmentation is provided at country-level per-region—North America (U.S., Canada and Mexico), Europe (U.K., France, Germany and others), Asia-Pacific (India, China and Australia) and LAMEA (Gulf Cooperation Council). Key market players include Medtronic plc, Dexcom, Inc., Abbott Diabetes Care, Animas Corporation, including others. The major strategies adopted by the market players across geographies are collaborations, product launches and approvals. Collaborations in the regions focus on innovation, distribution and commercialization of the devices.
KEY BENEFITS
The CGMS market is segmented based on components, customer segments, end-user demographics and geography (country-level).
The global CGMS market is forecast to reach $2.9 billion by 2021 registering a CAGR of 31.4% over the forecast period. The pipeline of high-tech CGMS devices, such as smartphone-connected CGMS, wearable and smartphone-connected CGMS, non-invasive CGMS and ‘smart’ diabetes management solution (also called artificial/bionic pancreas), would result in larger adoption of CGMS among endocrinologists and patients.
The market is categorized based on components, customer segments, end-user demographics and geographic regions. The CGMS components market includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. The segment for sensors occupies a dominant share in the CGMS market primarily due to the recurring sales of CGMS, short scrap life and bulk purchases. CGMS are deployed primarily by the diagnostic centers/clinics. Moreover, increasing usage of CGMS across the hospital ICUs and in-home healthcare settings has been observed. The CGMS devices market by age demographics is categorized as juveniles, Gen X and geriatrics.
Detailed geographical analysis and segmentation is provided at country-level per-region—North America (U.S., Canada and Mexico), Europe (U.K., France, Germany and others), Asia-Pacific (India, China and Australia) and LAMEA (Gulf Cooperation Council). Key market players include Medtronic plc, Dexcom, Inc., Abbott Diabetes Care, Animas Corporation, including others. The major strategies adopted by the market players across geographies are collaborations, product launches and approvals. Collaborations in the regions focus on innovation, distribution and commercialization of the devices.
KEY BENEFITS
- In-depth and country-level analysis within all the geographic regions would provide a clear understanding of current and future trends in the CGMS market
- Comprehensive analysis of factors that drive and restrict the growth of the CGMS market is provided
- The report covers detailed quantitative analysis of the current market and estimations through 2014–2021, which would enable the stakeholders to capitalize on prevailing market opportunities
- A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
- An in-depth analysis of current research and clinical developments within CGMS market is provided with key market dynamic factors that help in understanding the behavior of market
- Key market players within the CGMS market are profiled in the report and their strategies are analyzed thoroughly, which help in understanding the competitive outlook of the global CGMS market
The CGMS market is segmented based on components, customer segments, end-user demographics and geography (country-level).
- Global CGMS Market - by Components
- Sensors
- Transmitters & Receivers
- Integrated insulin pumps
- Global CGMS Market - by Customer Segments
- Diagnostics/Clinic
- ICUs
- Home Healthcare
- Global CGMS Market - by End-user Demographics
- Juveniles
- Gen X
- Geriatrics/undiagnosed
- Global CGMS Market - by Geography
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Others
- Asia-Pacific
- China
- India
- Australia
- Others
- LAMEA
- Gulf Cooperation Council (GCC)
- Others
CHAPTER: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER: 2 EXECUTIVE SUMMARY
CHAPTER: 3 MARKET OVERVIEW
3.1 Market definition
3.2 Need for glucose monitoring systems
3.2.1 Diabetes – a pandemic
3.2.1.1 Type 1 diabetes
3.2.1.2 Type-2 diabetes
3.2.1.3 Pre-diabetes and Gestational Diabetes Mellitus (GDM)
3.2.1.4 Gestational Diabetes Mellitus (GDM)
3.2.1.5 Secondary diabetes
3.2.2 Global healthcare expenditure on diabetes
3.3 Emerging technologies in CGMS
3.3.1 Smartphone-connected CGMS
3.3.2 Wearable and smartphone-connected CGMS
3.3.3 Non-invasive CGMS
3.3.4 Invasive CGMS in the R&D pipeline
3.3.5 'Smart’ diabetes management solution – Bionic Pancreas
3.4 CGMS - Prime end user segments
3.4.1 CGMS – crucial need in Intensive Care Units (ICUs)
3.4.1.1 ‘Stress Hyperglycemia’ – common occurrence in ICUs
3.4.1.2 Non-standardization and erroneous glycemic control across ICUs
3.4.2 Benefits and factors driving adoption of CGMS in ICUs
3.4.2.1 CGMS aid in Tight Glycemic Control in ICUs
3.4.2.2 Cost benefits from usage of CGMS
3.4.2.3 POC Glucometers less effective in ICUs - as compared to CGMS
3.4.2.4 CGMS – most preferred by ICU staff
3.5 Key findings
3.5.1 Top impacting factors
3.5.2 Top investment pockets
3.5.2.1 CGMS market –By End User Segments
3.5.2.2 CGMS market – by geography
3.5.3 Top winning strategies
3.6 Value chain analysis
3.7 Market share analysis, 2014
3.8 Government regulations
3.9 Reimbursement scenario
3.10 Drivers
3.10.1 Rise in incidence of diabetes globally
3.10.2 Inherent benefits of CGMS over POC glucometers – drive market growth
3.10.3 Increase in awareness in developing and underdeveloped economies
3.10.4 Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver
3.10.5 FDA, U.S. approval of Bionic Pancreas – future growth driver
3.11 Restraints
3.11.1 Stringent regulatory requirements
3.11.2 Inadequate reimbursements—a barrier in CGMS adoption
3.11.3 Accuracy and cost—a hindrance in continuing use of CGMS
3.12 Opportunities
3.12.1 Higher adoption rate of CGMS in ICUs
3.12.2 OTC/POC CGMS - expanded product applications/usage
3.12.3 ‘Undiagnosed’ patient population
3.13 Winning strategies for MNCs for entering emerging markets
3.13.1 Gaining CE approvals for a speedier entry into Asia-Pacific and LAMEA markets
3.13.2 Forming distribution alliances to enhance geographical reach
3.13.3 Raising end-user awareness and competitive product pricing
CHAPTER: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS
4.1 Stand-alone and Integrated CGM systems
4.1.1 Market size and forecast
4.2 Sensors
4.2.1 Key market trends
4.2.1.1 Non-invasive glucose sensors
4.2.1.2 Subcutaneous sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional technology—holter-yype retrospective sensors
4.2.1.4 Advanced technology—Real-Time sensors
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Transmitters & Receivers
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Integrated Insulin pumps
4.4.1 Overview
4.4.2 Key market trends
4.4.3 Key growth factors and opportunities
4.4.4 Market size and forecast
CHAPTER: 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT
5.1 Market size and forecast
5.2 Diagnostic centers/clinics
5.2.1 Market size and forecast
5.3 ICUs
5.3.1 Market size and forecast
5.4 Home healthcare
5.4.1 Market size and forecast
CHAPTER: 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET – BY AGE DEMOGRAPHICS
6.1 Juveniles
6.2 Gen X
6.3 Geriatrics / undiagnosed
CHAPTER: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY
7.1 North America
7.1.1 Market size and forecast
7.1.2 U.S.
7.1.3 Canada
7.1.4 Mexico
7.2 Europe
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.4 France
7.2.4.1 Key market trends
7.2.4.2 Key growth factors and opportunities
7.2.5 Germany
7.2.5.1 Key market trends
7.2.5.2 Key growth factors and opportunities
7.2.6 U.K.
7.2.6.1 Key market trends
7.2.6.2 Key growth factors and opportunities
7.2.7 Other European countries
7.3 Asia-Pacific
7.3.1 Market size and forecast
7.3.2 India
7.3.2.1 Key market trends
7.3.3 Australia
7.3.3.1 Key market trends
7.3.4 China
7.3.4.1 Key market trends
7.3.5 Other APAC countries
7.4 LAMEA
7.4.1 Overview
7.4.2 Market size and forecast
7.4.3 Gulf Cooperation Council (GCC)
7.4.3.1 Key market trends
CHAPTER: 8 COMPANY PROFILES
8.1 Medtronic Plc.
8.1.1 Company overview
8.1.2 Business performance
8.1.3 Strategic moves and developments
8.1.3.1 Principal strategies: product launch
8.1.3.2 Secondary strategies: approval
8.1.3.3 Other strategies: strategic alliance and collaboration
8.1.4 SWOT analysis of Medtronic Plc
8.2 Dexcom Inc.
8.2.1 Company overview
8.2.2 Business performance
8.2.3 Strategic moves and developments
8.2.3.1 Principal strategies: agreement/partnership
8.2.3.2 Secondary strategies: approval
8.2.3.3 Other strategies: acquisition
8.2.4 SWOT analysis of Dexcom
8.3 Abbott Diabetic Care (Abbott Laboratories)
8.3.1 Company overview
8.3.2 Business performance
8.3.3 Strategic moves and developments
8.3.4 SWOT analysis of Abbott diabetic care
8.4 Animas Corporation
8.4.1 Company overview
8.4.2 Strategic moves and developments
8.4.3 SWOT analysis of Animas Corporation
8.5 Echo Therapeutics
8.5.1 Company Overview
8.5.2 Strategic moves and development
8.5.3 SWOT Analysis of Echo Therapeutics
8.6 Insulet Corporation
8.6.1 Company overview
8.6.2 Strategic moves and developments
8.6.3 SWOT analysis of INSULET Corporation
8.7 Glysens Inc.
8.7.1 Company overview
8.7.2 Strategic moves and developments
8.7.3 SWOT Analysis of Glysens Inc.
8.8 Senseonics, Inc.
8.8.1 Company overview
8.8.2 Strategic moves and development
8.8.3 SWOT analysis of Senseonics, Inc.
List of Figures
FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS – SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20–79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010–2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES, 2013 (MILLION)
FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER: 2 EXECUTIVE SUMMARY
CHAPTER: 3 MARKET OVERVIEW
3.1 Market definition
3.2 Need for glucose monitoring systems
3.2.1 Diabetes – a pandemic
3.2.1.1 Type 1 diabetes
3.2.1.2 Type-2 diabetes
3.2.1.3 Pre-diabetes and Gestational Diabetes Mellitus (GDM)
3.2.1.4 Gestational Diabetes Mellitus (GDM)
3.2.1.5 Secondary diabetes
3.2.2 Global healthcare expenditure on diabetes
3.3 Emerging technologies in CGMS
3.3.1 Smartphone-connected CGMS
3.3.2 Wearable and smartphone-connected CGMS
3.3.3 Non-invasive CGMS
3.3.4 Invasive CGMS in the R&D pipeline
3.3.5 'Smart’ diabetes management solution – Bionic Pancreas
3.4 CGMS - Prime end user segments
3.4.1 CGMS – crucial need in Intensive Care Units (ICUs)
3.4.1.1 ‘Stress Hyperglycemia’ – common occurrence in ICUs
3.4.1.2 Non-standardization and erroneous glycemic control across ICUs
3.4.2 Benefits and factors driving adoption of CGMS in ICUs
3.4.2.1 CGMS aid in Tight Glycemic Control in ICUs
3.4.2.2 Cost benefits from usage of CGMS
3.4.2.3 POC Glucometers less effective in ICUs - as compared to CGMS
3.4.2.4 CGMS – most preferred by ICU staff
3.5 Key findings
3.5.1 Top impacting factors
3.5.2 Top investment pockets
3.5.2.1 CGMS market –By End User Segments
3.5.2.2 CGMS market – by geography
3.5.3 Top winning strategies
3.6 Value chain analysis
3.7 Market share analysis, 2014
3.8 Government regulations
3.9 Reimbursement scenario
3.10 Drivers
3.10.1 Rise in incidence of diabetes globally
3.10.2 Inherent benefits of CGMS over POC glucometers – drive market growth
3.10.3 Increase in awareness in developing and underdeveloped economies
3.10.4 Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver
3.10.5 FDA, U.S. approval of Bionic Pancreas – future growth driver
3.11 Restraints
3.11.1 Stringent regulatory requirements
3.11.2 Inadequate reimbursements—a barrier in CGMS adoption
3.11.3 Accuracy and cost—a hindrance in continuing use of CGMS
3.12 Opportunities
3.12.1 Higher adoption rate of CGMS in ICUs
3.12.2 OTC/POC CGMS - expanded product applications/usage
3.12.3 ‘Undiagnosed’ patient population
3.13 Winning strategies for MNCs for entering emerging markets
3.13.1 Gaining CE approvals for a speedier entry into Asia-Pacific and LAMEA markets
3.13.2 Forming distribution alliances to enhance geographical reach
3.13.3 Raising end-user awareness and competitive product pricing
CHAPTER: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS
4.1 Stand-alone and Integrated CGM systems
4.1.1 Market size and forecast
4.2 Sensors
4.2.1 Key market trends
4.2.1.1 Non-invasive glucose sensors
4.2.1.2 Subcutaneous sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional technology—holter-yype retrospective sensors
4.2.1.4 Advanced technology—Real-Time sensors
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Transmitters & Receivers
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Integrated Insulin pumps
4.4.1 Overview
4.4.2 Key market trends
4.4.3 Key growth factors and opportunities
4.4.4 Market size and forecast
CHAPTER: 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT
5.1 Market size and forecast
5.2 Diagnostic centers/clinics
5.2.1 Market size and forecast
5.3 ICUs
5.3.1 Market size and forecast
5.4 Home healthcare
5.4.1 Market size and forecast
CHAPTER: 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET – BY AGE DEMOGRAPHICS
6.1 Juveniles
6.2 Gen X
6.3 Geriatrics / undiagnosed
CHAPTER: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY
7.1 North America
7.1.1 Market size and forecast
7.1.2 U.S.
7.1.3 Canada
7.1.4 Mexico
7.2 Europe
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.4 France
7.2.4.1 Key market trends
7.2.4.2 Key growth factors and opportunities
7.2.5 Germany
7.2.5.1 Key market trends
7.2.5.2 Key growth factors and opportunities
7.2.6 U.K.
7.2.6.1 Key market trends
7.2.6.2 Key growth factors and opportunities
7.2.7 Other European countries
7.3 Asia-Pacific
7.3.1 Market size and forecast
7.3.2 India
7.3.2.1 Key market trends
7.3.3 Australia
7.3.3.1 Key market trends
7.3.4 China
7.3.4.1 Key market trends
7.3.5 Other APAC countries
7.4 LAMEA
7.4.1 Overview
7.4.2 Market size and forecast
7.4.3 Gulf Cooperation Council (GCC)
7.4.3.1 Key market trends
CHAPTER: 8 COMPANY PROFILES
8.1 Medtronic Plc.
8.1.1 Company overview
8.1.2 Business performance
8.1.3 Strategic moves and developments
8.1.3.1 Principal strategies: product launch
8.1.3.2 Secondary strategies: approval
8.1.3.3 Other strategies: strategic alliance and collaboration
8.1.4 SWOT analysis of Medtronic Plc
8.2 Dexcom Inc.
8.2.1 Company overview
8.2.2 Business performance
8.2.3 Strategic moves and developments
8.2.3.1 Principal strategies: agreement/partnership
8.2.3.2 Secondary strategies: approval
8.2.3.3 Other strategies: acquisition
8.2.4 SWOT analysis of Dexcom
8.3 Abbott Diabetic Care (Abbott Laboratories)
8.3.1 Company overview
8.3.2 Business performance
8.3.3 Strategic moves and developments
8.3.4 SWOT analysis of Abbott diabetic care
8.4 Animas Corporation
8.4.1 Company overview
8.4.2 Strategic moves and developments
8.4.3 SWOT analysis of Animas Corporation
8.5 Echo Therapeutics
8.5.1 Company Overview
8.5.2 Strategic moves and development
8.5.3 SWOT Analysis of Echo Therapeutics
8.6 Insulet Corporation
8.6.1 Company overview
8.6.2 Strategic moves and developments
8.6.3 SWOT analysis of INSULET Corporation
8.7 Glysens Inc.
8.7.1 Company overview
8.7.2 Strategic moves and developments
8.7.3 SWOT Analysis of Glysens Inc.
8.8 Senseonics, Inc.
8.8.1 Company overview
8.8.2 Strategic moves and development
8.8.3 SWOT analysis of Senseonics, Inc.
List of Figures
FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS – SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20–79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010–2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES, 2013 (MILLION)
FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.
LIST OF TABLES
TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)
TABLE 3 GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 4 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014–2021 ($MILLION)
TABLE 5 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 6 GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014–2021 ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)
TABLE 8 GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 9 GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 10 GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 11 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 12 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021
TABLE 13 GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 14 NORTH AMERICA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 15 NORTH AMERICA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 18 EUROPE CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 19 TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035
TABLE 20 PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035
TABLE 21 APAC CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 22 APAC CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 23 MEDICAL DEVICES USED IN AUSTRALIA
TABLE 24 LAMEA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 25 LAMEA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 26 MEDTRONIC BUSINESS SNAPSHOT
TABLE 27 MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
TABLE 28 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 29 ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
TABLE 30 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 31 ECHO THERAPEUTICS COMPANY SNAPSHOT
TABLE 32 INSULET CORPORATION BUSINESS SNAPSHOT
TABLE 33 GLYSENS INC. BUSINESS SNAPSHOT
TABLE 34 SENSEONICS, INC. SNAPSHOT
TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)
TABLE 3 GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 4 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014–2021 ($MILLION)
TABLE 5 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 6 GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014–2021 ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)
TABLE 8 GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 9 GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 10 GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 11 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 12 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021
TABLE 13 GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 14 NORTH AMERICA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 15 NORTH AMERICA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 18 EUROPE CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 19 TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035
TABLE 20 PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035
TABLE 21 APAC CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 22 APAC CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 23 MEDICAL DEVICES USED IN AUSTRALIA
TABLE 24 LAMEA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 25 LAMEA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 26 MEDTRONIC BUSINESS SNAPSHOT
TABLE 27 MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
TABLE 28 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 29 ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
TABLE 30 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 31 ECHO THERAPEUTICS COMPANY SNAPSHOT
TABLE 32 INSULET CORPORATION BUSINESS SNAPSHOT
TABLE 33 GLYSENS INC. BUSINESS SNAPSHOT
TABLE 34 SENSEONICS, INC. SNAPSHOT
LIST OF FIGURES
FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS – SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20–79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010–2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES, 2013 (MILLION)
FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.
FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS – SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20–79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010–2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES, 2013 (MILLION)
FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.
